Eli Lilly & Co.’s blockbuster obesity shot Zepbound helped people with type 1 diabetes lose more than a fifth of their body ...

The injectable weight-loss drug Zepbound appears to work better in women than in men, according to a new analysis.

Many people are doing an end-run around their doctor's office, reaching out to potentially unreliable sources that promise to ...

The move to self-administration with a syringe and needle, just like how insulin is often taken for diabetes, means a whole ...

Obesity-focused biotech BioAge Labs said on Wednesday it was seeking a valuation of as much as $587 million in its initial public offering in the United States, according to a regulatory filing.

The S&P 500 ended 0.3% lower on Wednesday, Sept. 18, 2024, as the Federal Reserve announced its first interest-rate cut since ...

Healthcare firms have done comparatively well in an otherwise subdued U.S. IPO market in 2024, which analysts touted as a comeback year for public offerings. The Richmond, California-based company ...

The company shipped some 750 vials of testosterone to customers who had instead ordered tirzepatide, the active ingredient in ...

U.S. telehealth company Hims & Hers Health on Wednesday said it will sell compounded versions of Novo Nordisk's popular ...

There is soaring demand for weight-loss drugs in the GLP-1 class, and the company will now sell it to certain professions for ...

Healthcare technology company ResMed 's (NYSE: RMD) stock wasn't quite the picture of health on Wednesday. The shares lost more than 5% of their value on news of an analyst's downgrade and his new, ...

More research is needed to understand why the drug works better for women Get any of our free email newsletters — news ...